Having invested a little over £100m ($134m) into its portfolio over the past two financial years, venture capital firm Arix Bioscience is building a considerable reputation for itself in the life sciences segment.
Arix is fresh from a $71m public listing for its cancer immunotherapy portfolio company Harpoon Therapeutics in February, and now hopes to find new oncology approaches to drive further growth, as the market for cell and gene cancer medicines becomes more crowded.
Jonathan Tobin, an investment director at Arix specialised in biotechnology said: “Everyone is going to be interested in oncology as an area – at least 40%, if not half, of all deal flow in venture is oncology…
